- Previous Close
143.23 - Open
142.00 - Bid 138.71 x 100
- Ask 139.20 x 100
- Day's Range
138.67 - 143.40 - 52 Week Range
110.45 - 211.13 - Volume
359,418 - Avg. Volume
838,282 - Market Cap (intraday)
7.787B - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
-- - EPS (TTM)
-0.03 - Earnings Date Oct 29, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
193.32
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
www.repligen.com1,783
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: RGEN
View MorePerformance Overview: RGEN
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGEN
View MoreValuation Measures
Market Cap
8.02B
Enterprise Value
7.96B
Trailing P/E
466.37
Forward P/E
77.52
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.35
Price/Book (mrq)
4.04
Enterprise Value/Revenue
13.21
Enterprise Value/EBITDA
86.52
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.32%
Return on Assets (ttm)
0.19%
Return on Equity (ttm)
-0.10%
Revenue (ttm)
602.35M
Net Income Avi to Common (ttm)
-1.9M
Diluted EPS (ttm)
-0.03
Balance Sheet and Cash Flow
Total Cash (mrq)
809.15M
Total Debt/Equity (mrq)
37.40%
Levered Free Cash Flow (ttm)
120.45M
Research Analysis: RGEN
View MoreCompany Insights: RGEN
RGEN does not have Company Insights
Research Reports: RGEN
View MoreRepligen: Initiating Coverage With Narrow Moat Rating and $180 FVE; Shares Undervalued
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
RatingPrice TargetWhat does Argus have to say about RGEN?
REPLIGEN CORP has an Investment Rating of SELL; a target price of $120.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $118.00
REPLIGEN CORP has an Investment Rating of SELL; a target price of $118.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $120.00
REPLIGEN CORP has an Investment Rating of SELL; a target price of $120.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target